Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul J Fudala

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Current Psychiatry Reports|September 10, 2004
Recent advances in the treatment of opiate addictionPaul J Fudala, George W Woody
Drug and Alcohol Dependence|March 28, 2006
Development of opioid formulations with limited diversion and abuse potentialPaul J Fudala, Rolley E Johnson
Drug and Alcohol Dependence Reports|March 30, 2023
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorderChristian Heidbreder, Paul J Fudala, Mark K Greenwald
Journal of Pain and Symptom Management|March 23, 2005
Buprenorphine: considerations for pain managementRolley E Johnson, Paul J Fudala, Richard Payne
Clinical Pharmacokinetics|January 22, 2015
Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy VolunteersAzmi F Nasser, Christian Heidbreder, Yongzhen Liu, et al.
Drug and Alcohol Dependence|May 10, 2003
Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependenceT Peter Bridge, Paul J Fudala, Susan Herbert, et al.
Addiction (Abingdon, England)|February 1, 2005
Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug usersLynn E Sullivan, David S Metzger, Paul J Fudala, et al.
Journal of Addictive Diseases|October 10, 2014
A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effectsAzmi F Nasser, Paul J Fudala, Bo Zheng, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|August 27, 2003
An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studiesPaul J Fudala, Robert M Weinrieb, Joseph S Calarco, et al.
Clinical Pharmacokinetics|January 28, 2014
Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatmentCeline M Laffont, Roberto Gomeni, Bo Zheng, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Psychiatry Reports|September 10, 2004
Recent advances in the treatment of opiate addictionPaul J Fudala, George W Woody
Drug and Alcohol Dependence|March 28, 2006
Development of opioid formulations with limited diversion and abuse potentialPaul J Fudala, Rolley E Johnson
Drug and Alcohol Dependence Reports|March 30, 2023
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorderChristian Heidbreder, Paul J Fudala, Mark K Greenwald
Journal of Pain and Symptom Management|March 23, 2005
Buprenorphine: considerations for pain managementRolley E Johnson, Paul J Fudala, Richard Payne
Clinical Pharmacokinetics|January 22, 2015
Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy VolunteersAzmi F Nasser, Christian Heidbreder, Yongzhen Liu, et al.
Drug and Alcohol Dependence|May 10, 2003
Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependenceT Peter Bridge, Paul J Fudala, Susan Herbert, et al.
Addiction (Abingdon, England)|February 1, 2005
Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug usersLynn E Sullivan, David S Metzger, Paul J Fudala, et al.
Journal of Addictive Diseases|October 10, 2014
A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effectsAzmi F Nasser, Paul J Fudala, Bo Zheng, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|August 27, 2003
An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studiesPaul J Fudala, Robert M Weinrieb, Joseph S Calarco, et al.
Clinical Pharmacokinetics|January 28, 2014
Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatmentCeline M Laffont, Roberto Gomeni, Bo Zheng, et al.
Pageof 3